Phase 3 of FORTIFY for Limb-Girdle Muscular Dystrophy Type 2i saw the beginning of dosing.

Published Date: 13 Aug 2023

The FDA and BridgeBio Pharma met to discuss the use of glycosylated -dystroglycan levels as a surrogate end point for the phase 3 trial FORTIFY investigating BBP-418. BridgeBio Pharma believes there is a chance for an accelerated approval.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot